...
首页> 外文期刊>Bioorganic and medicinal chemistry >Carbonic anhydrase inhibitors: Synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety
【24h】

Carbonic anhydrase inhibitors: Synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety

机译:碳酸酐酶抑制剂:带有4,5,6,7-四溴邻苯二甲酰亚胺部分的苯磺酰胺的合成和抑制人碳酸酐酶同工型I,II,VII,IX和XII

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A series of 4,5,6,7-tetrabromo-1,3-dioxoisoindolin-2-yl benzenesulfonamide derivatives (compounds 1-8) was synthesized by reaction of benzene sulfonamide derivatives with 4,5,6,7-tetrabromophthalic anhydride moiety. These new sulfonamides were investigated as inhibitors of the zinc metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) and more specifically against the human (h) cytosolic isoforms hCA I, II and VII and the transmembrane tumor-associated isoform hCA IX and XII. The new compounds were good hCA I inhibitors (Kis in the range of 143 to >10,000 nM), but were moderately effective, as hCA II inhibitors (Kis of 47-190 nM) and poor hCA VII inhibitors (Kis in the range of 54-175 nM) compared to acetazolamide. The tumor-associated hCA IX was effectively inhibited with Kis ranging between 8.5 and 234 nM and hCA XII with inhibition constants in the range of 6.1-197 nM with high selectivity ratio. The structure-activity relationship (SAR) with this series of sulfonamides is straightforward, with the main features leading to good activity for each isoforms being established. The high sequence hCA alignment homology and molecular docking study of compounds was performed to rationalize the SAR reported over here.
机译:通过苯磺酰胺衍生物与4,5,6,7-四溴邻苯二甲酸酐部分的反应,合成了一系列4,5,6,7-四溴-1,3-二氧异吲哚-2-基苯磺酰胺衍生物(化合物1-8) 。研究了这些新的磺酰胺作为锌金属酶碳酸酐酶(CA,EC 4.2.1.1)的抑制剂,更具体地针对人(h)胞质同工型hCA I,II和VII和跨膜肿瘤相关同工型hCA IX和XII。新化合物是良好的hCA I抑制剂(Kis在143到> 10,000 nM范围内),但作为hCA II抑制剂(Kis在47-190 nM)和较差的hCA VII抑制剂(Kis在54范围内)效果中等-175 nM)与乙酰唑胺相比。与肿瘤相关的hCA IX被有效抑制,其Kis范围在8.5至234 nM之间,hCA XII的抑制常数在6.1-197 nM之间,具有高选择性。该系列磺酰胺的结构活性关系(SAR)很简单,其主要特征是可以为每种同工型建立良好的活性。进行了化合物的高序列hCA比对同源性和分子对接研究,以合理化此处报道的SAR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号